Business Context and Reporting Period
Company: ChromaDex Corporation (Note: Request metadata listed "Niagen Bioscience, Inc.", but the filing identifies the registrant as ChromaDex Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: November 29, 2009
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics and Transaction Details
This filing details a private placement offering rather than standard operating financial results. Key transaction metrics include:
- Initial Capital Raised: $500,000
- Initial Shares Sold: 958,406 shares of common stock
- Price Per Share: $0.5217
- Investor: Jinke Group (Hong Kong) Ltd
- Warrants Issued: 1,333,334 shares at an exercise price of $0.80 per share (5-year term).
- Conditional Second Sale: Investor subscribed to purchase an additional 958,405 shares for $500,000 by December 20, 2009. If completed, total capital raised would be $1,000,000 for 1,916,811 shares.
Liquidity and Debt: The filing text does not provide a clear value for total cash on hand, existing debt, or liquidity ratios outside of the specific capital raised in this transaction.
Material Changes and Conditions
The primary material change is the issuance of equity and warrants to a single investor. Specific conditions attached to the transaction include:
- Warrant Reduction: If the Second Sale is not completed by December 20, 2009, the warrant count automatically reduces from 1,333,334 to 666,667 shares.
- Warrant Exercisability: 666,667 warrant shares are immediately exercisable. The remaining 666,667 are exercisable only after the Second Sale consideration is tendered and after December 21, 2009.
- Acceleration Clause: Warrants have an accelerated expiration if the stock trades at or above $1.60 for 90 consecutive trading days.
- Registration Rights: Investor received piggy-back and demand registration rights (exercisable after five years for proceeds of at least $1,000,000).
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations.
Risks and Contingencies:
- Dilution Risk: Significant dilution potential exists if the Second Sale is completed and warrants are exercised.
- Market Price Risk: The transaction price ($0.5217) is below the warrant exercise price ($0.80) and the acceleration trigger ($1.60).
- Contingency: The total capital raise is contingent on the Investor tendering the second $500,000 payment by the specified deadline.
Important Facts for Investor Verification
- Verify the completion status of the "Second Sale" ($500,000) by December 20, 2009, as this determines the total capital raised and the number of warrants outstanding.
- Confirm the current trading price of ChromaDex stock relative to the $1.60 acceleration trigger for the warrants.
- Review the full Subscription Agreement (Exhibit 10.1) for additional covenants or restrictions not summarized in the 8-K.
- Check subsequent filings to determine if the company has met the $1,000,000 threshold required for the Investor to exercise demand registration rights.